INTRODUCTION

Depletion of phosphatases and Ras by RNA interference.
For phosphatome analysis A549 cells were transfected with 40 nmoles (per 1x10 5 cells) of each siRNA pool using oligofectamine (Invitrogen). 24 hours posttransfection the cells were re-seeded and two days post-transfection, cells were re-transfected with siRNA; 24 h later (72 hours total knockdown time) the cells were lysed for Western blot analysis. Cells were grown throughout in the presence of 10% FCS unless otherwise stated. The large-scale screen was performed once in A549 cells with the top twenty hits chosen for comparative analysis in Panc-08-13 cells. All RNAi experiments with the leading hits (single or combined knockdowns with K-Ras) were repeated at least four times with 40 nmoles of each duplex, identical results were observed for each pair of oligonucleotides. Analysis of specific phosphatase knockdown and effector pathway activation was confirmed by Western blotting lysates resolved on NuPAGE 4-12% Bis-Tris gels (Invitrogen) and measured by quantitative analysis of Western blots using the Odyssey (LI-COR Biosciences) digital imaging system.
Where indicated, control and RNAi treated cells were serum-starved for 6 hours before being stimulated for 10 minutes with 100ng/ml of EGF, washed once with ice-cold PBS and lysed for 5-10 min on ice in a lysis buffer containing 0.5% NP-40, 25mM Tris pH 7.5, 100mM NaCl, 50mM NaF, supplemented with mammalian protease inhibitor cocktail and mammalian phosphatase inhibitor cocktail II (Sigma). Lysates were probed for effector activation using quantitative Western blotting.
Ras activation assay.
Sub-confluent cells were serum-starved over-night before being stimulated by 100ng/ml of EGF for 10 minutes. The cells were then washed with ice-cold PBS and lysed on ice in 50 mM Tris-HCl, pH 7.2, 500mM NaCl, 10mM MgCl 2 , 1% Triton X-100, 0.5% sodium deoxycholate, 1:250 protease-inhibitor cocktail (Sigma). 15 g of GST-RBD K85A fusion protein linked to Glutathione Sepharose(4B) was used to affinity purify activated Ras from 200 g of each lysate as described [11] . Pull downs were immuno-blotted for Ras isoforms and pan-Ras.
RESULTS
Oncogenic K-Ras is uncoupled from effector activation.
A549 and Panc-08-13 cells harbour K-Ras that is homozygously mutated at the G12 position ( Figure 1A ); mutation at this position is known to render Ras constitutively active and transforming [2, 13] . Previous analysis of Ras isoform abundance indicated that K-Ras represents 50% of the total Ras pool in A549 cells [5] . As expected, A549 cells harbouring mutant K-Ras displayed equivalent levels of significant K-Ras activation regardless of the presence or absence of serum overnight or acute saturating 100 ng/ml EGF stimulation ( Figure 1B) . In contrast, the activity of endogenous wild type K-Ras in HeLa cells and the other Ras isoforms in both cell lines significantly increases in response to acute EGF stimulation. Pan-Ras activation in A549 cells is dominated by K-Ras and A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
consequently barely increases in response to EGF. Taken together with the data on K-Ras abundance and mutation status this means that in A549 cells 50% of the total Ras pool is activated to a level that is 90-100% of that seen with maximal acute EGF stimulation ( Figure 1B) .
Given the presence of a significant pool of active Ras in A549 and Panc-08-13 cells there is an unexpected lack of robust activation of the main Ras effector pathways: Raf-MEK-ERK and PtdIns-3-kinase-Akt ( Figure 1C ). We observe reduced or minimal pMEK, pERK and pAkt under continuous culture conditions in the presence of FBS, however these pathways are still able to robustly respond to acute growth factor stimulation. In A549 and HeLa cells we see an equivalent increase in pAkt and pERK labeling with acute EGF stimulation. This indicates that the low outputs seen under steady state culture conditions are due to specific uncoupling of the signal from oncogenic K-Ras rather than a complete down-regulation of these pathways.
Phosphatome screening for oncogenic Ras regulators.
Ras-dependent activation of ERK and Akt involves a series of intermediary kinases and accessory proteins regulated by phosphorylation. We reasoned that the dampened Ras output in A549 cells was likely to be at least partially dependent on the up-regulation of expression or specific activity of one or more phosphatases. To identify these potential regulators we performed a phosphatome RNAi screen incorporating approximately 85% of all tyrosine, serine and threonine phosphatases (Supplementary Table 1 ). These included all 37 classical protein tyrosine phosphatases (PTPs), 48/66 Dual-specificity or VH1-like phosphatases (DUSPs), 27/31 Ser/Thr phosphatases and 40/51 regulatory subunits of Ser/Thr phosphatases [14] . Any phosphatases directly or indirectly negatively regulating Ras outputs would be expected to cause an increase in pAkt or pERK when knocked down.
The screen was carried out under steady state tissue culture conditions containing FBS; the result of each phosphatase knockdown was normalized to tubulin to control for loading and then compared to acute EGF stimulated positive controls loaded on the same gels. The scores from all 244 knockdowns were placed in rank order; for pERK labelling the leading hits generated 20-25% of the maximal signal observed following acute EGF stimulation (Figure 2 ). In comparison, control mock-transfected A549 cells that were not incubated with EGF generated an average of 12.6% of maximal pERK labelling. This value is at the upper end of the range of the standard deviation from the mean indicating that compared to an unstimulated mock transfected control the majority of the phosphatase knockdowns had a relative inhibitory effect on pERK production.
Parallel analysis of Akt phosphorylation revealed a far more significant impact of phosphatase knockdown on this pathway compared to MAPK activation with leading hits restoring Akt activation to 60-70% of that seen with acute EGF stimulation ( Figure 3A) . The mock-transfected, unstimulated controls produced an average of 32.4% of maximal pAkt labeling -close to the mean value for this dataset.
A necessary step in Akt activation is recruitment to the cell surface via interaction of its PH-domain with phosphatidylinositol-3,4,5-trisphosphate A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
(PtdInsP3) produced by PtdIns-3-kinase. One of our leading hits -PTEN is a PtdInsP3 3-phosphatase that has been well characterized as a critical and ubiquitous negative regulator of the PtdIns-3-kinase function [15] . Similarly, although the ubiquitously expressed inositol-5-phosphatase SHIP2 was not in our screen, knockdown of a related family member -INPP5E significantly derepressed Akt activation. Importantly, our unbiased screen reveals several other phosphatases with similarly potent effects to PTEN at regulating Akt phosphorylation. These included PTPN2 and PTPRJ known regulators of receptor tyrosine kinase activity; and PPAP2A a phosphatidic acid phosphatase whose knockdown would result in increased cellular phosphatidic acid -a known facilitator of Ras activation [16] .
Identification of potent regulators of Akt phosphorylation.
Due to the robustness of the response we decided to focus on leading phosphatases modulating Akt phosphorylation. The large scale of the phosphatome screen precludes direct validation of every data point. Therefore, we performed a limited phosphatome RNAi screen in Panc-08-13 cells focusing on the top 20 pAkt hits plus five phosphatases that had average responses in A549 cells (Supplementary Table 1 ). Seven phosphatases were chosen for detailed follow-up based on best aggregate performance in the screens with the two cell lines.
The phosphatome screen used a pool of four oligos specific to each phosphatase -we deconvolved these four oligos and looked for at least 3 of the 4 to re-confirm the phenotype in A549 cells to increase confidence in the data ( Figure 3B ). PPAP2A, PTEN, PTPN2 and PTPRJ all met this criterion. Whilst RNAi typically produced a 75-90% knockdown of each phosphatase, in the case of PPAP2A we observed no evidence of specific knockdown ( Figure 3C ). This was despite using two separate antibodies that could recognize all isoforms of PPAP2A (data not shown); therefore, the results for PPAP2A are likely to represent an off-target effect.
Our screen is performed under tissue culture conditions where serum is present. This has the potential to reveal general regulators of RTK-Akt activation that may be independent of oncogenic Ras. In order to investigate the Rasdependence we performed combined phosphatase-Ras knock-downs. If the phosphatases are contingent on oncogenic Ras then the increased Akt phosphorylation seen with phosphatase knockdown should be significantly reduced when K-Ras expression is also lost. This is exactly what we observe with PTEN/K-Ras and PTPRJ/K-Ras double knockdowns implicating these phosphatases as the two main negative regulators of oncogenic Ras-dependent activation of Akt in these cells (Figure 4 ). In contrast, PTPN2 knockdown significantly increases Akt phosphorylation but shows no coupling to K-Ras (Figure 4 ).
DISCUSSION
Our screen revealed many phosphatases whose knockdown potentiated Akt and ERK phosphorylation, several of which have not previously been implicated in regulating these pathways. We ranked the relative contributions of A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
phosphatases in regulating the main Ras effector pathways and revealed specific antagonists of oncogenic Ras signaling. We also showed that co-operating mutations within the same pathway are needed to overcome cellular regulation and achieve full signaling potential. Each of these points is discussed below.
Identification of negative regulators of Ras pathways.
We focused on Ras activation of Akt and identified PTPN2, PTPRJ and PTEN as potent regulators of this pathway. PTEN is the archetypal negative regulator of PtdIns-3-kinase signalling and is frequently mutated in cancer [17] . Whilst it is perhaps no surprise to see PTEN as one of our leading hits it is significant that we have identified other phosphatases that are similarly potent regulators of this important signaling pathway.
The other two leading hits -PTPN2 and PTPRJ, are known negative regulators of RTKs. PTPN2 is a ubiquitously expressed, nuclear localised phosphatase with several RTKs as substrates [18] [19] [20] [21] . In response to EGF stimulation, PTPN2 translocates to the plasma membrane and dephosphorylates EGFR thereby decreasing PtdIns-3-kinase/Akt signalling [21] . Modulation of EGFR signaling was specific for PtdIns-3-kinase/Akt and had no inhibitory effect on ERK activation [22] , concordant with our screen. PTPRJ negatively regulates several RTKs including: EGFR, Met, PDGFR [23-26]; and is a known tumour suppressor mutated or lost in several cancer types [27, 28] . PTPRJ was a leading hit in both our pERK and pAkt screens however only 1 of the 4 oligos reproduced this pERK result whilst all 4 resulted in potentiation of Akt phosphorylation. Whilst our data indicated an off-target effect on pERK labelling another group recently showed that PTPRJ directly dephosphorylates ERK1/2 [29] .
Since the function of these phosphatases is linked to receptors upstream of Ras, their presence as leading hits may reflect an important general role in modulating RTK activation of PtdIns-3-kinase/Akt. In this case, loss of the phosphatase will result in enhanced RTK phosphorylation and consequent activation of wild type Ras and PtdIns-3-kinase. This stimulatory effect on PtdIns 3-kinase/Akt would be independent of oncogenic K-Ras activity. For PTPN2 at least this seems to be the case since knocking down K-Ras did not significantly alter the response (Figure 4) , indicating no requirement for oncogenic Ras. In contrast, PTPRJ shows significant coupling to oncogenic K-Ras indicating either co-operativity or upstream regulation of PTPRJ by K-Ras. The basis for this may be due to the role of PTPRJ in dephosphorylating residues within the inhibitory domain of the p85 subunit of PtdIns-3-kinase resulting in attenuated PtdIns-3-kinase activation [30] . Both tyrosine phosphorylation and Ras binding to the p85 subunit result in a synergistic activation of PtdIns-3-kinase [31] and the identification of PTPRJ as one of our most potent Akt activation hits may be a consequence of this synergism with oncogenic K-Ras. Alternatively PTPRJ may be in a feedback loop regulated by K-Ras -further work is required to differentiate between these possibilities.
Whilst we identified many phosphatases for which knockdown significantly modulated Akt and ERK phosphorylation none of our top hits were known direct inhibitory modulators of Raf-MEK-ERK or Akt such as PP5, PHLPP, PP2A and A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
DUSPs 6, 7 and 9 [32-34]. One explanation for these direct regulators not featuring in our leading lists is that we do not provide a pulse of growth factor stimulation. Our assay is primarily limited to oncogenic Ras driving signalling whereas acute application of growth factors will concurrently activate a network of Ras-independent effectors that may transiently stimulate phosphatases directly regulating pathways leading to Akt and ERK activation.
Co-operation between oncogenes and tumour suppressors.
The phosphatases that we have identified are either directly downstream of Ras function or are involved in down-regulating signal flow from RTKs and PtdIns-3-kinase. They appear to be capable of functioning in the absence of acute growth factor stimulation and may therefore represent important constitutive regulators of the basal state of the RTK-Ras-Akt pathway.
As discussed earlier, mutation of an oncogene is not necessarily sufficient for full tumour progression. Co-operating genetic lesions are needed to achieve full signaling potential and drive the tumourigenic process. This effect was clearly seen in our combined analysis of K-Ras and PTEN. Mutant K-Ras alone or loss of PTEN in the absence of mutant K-Ras could not maximize phospho-Akt labelling -however when combined we observed a synergy that generated significant Akt phosphorylation (Figure 4) . This co-operation may explain the in vivo observation that inactivation of PTEN significantly accelerates K-Ras initiated lung cancer compared to controls harbouring either one of these mutations [35] . Similarly, co-incident combinations of K-Ras, PtdIns-3-kinase p110 (PIK3CA) and PTEN mutations or disruption have been observed in endometrial, breast and colorectal cancers [36] .
Recent work using mouse models expressing oncogenic K-Ras G12D at endogenous levels in thyroid tissue revealed that Ras activation alone was not sufficient to induce visible neoplasia [37] . However, PTEN loss in combination with oncogenic Ras synergized to kill the entire cohort within 4 months of birth. Therefore, analogous to our study, oncogenic Ras displayed attenuated output that needed the removal of a key negative regulator to achieve its full oncogenic potential. This was achieved by generating constitutive PtdIns-3-kinase signalling that was also necessary for relieving inhibition of MAPK activation. Therefore understanding the tumour-specific interplay between oncogenic Ras, effector proteins and negative regulators has implications for therapeutic design and treatment. For example, drugs such as Iressa and Herceptin that target receptors upstream of PtdIns-3-kinase and Ras may be ineffective in the context of cancer cells that already down-regulate mutant Ras output. Similarly, whilst many Raf driven tumours respond to MEK inhibitors, Ras mutant cell lines are typically less sensitive -in part dependent on the extent of cross talk between the PtdIns-3-kinase and MAPK pathways mediated by co-incident mutations in PIK3CA or PTEN [38, 39] .
In summary, our work has provided clear examples where negative regulation is keeping in check the output of major fractions of total cellular Ras that are constitutively active. We have also identified many potential positive and negative regulators of the pathways leading to Akt and ERK activation and importantly, ranked their relative potencies at modulating these key signalling pathways. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
Amongst these, we have identified a group of phosphatases that rival PTEN for potency in regulating RTK-PtdIns-3-kinase-Akt signalling and revealed the synergy between oncogenic genetic perturbations within a pathway that are required to achieve full signalling potential. . Despite the presence of a significant pool of activated K-Ras, strong Akt and ERK phosphorylation is only seen following 10 minutes of 100 ng/ml EGF stimulation (C).
FUNDING
FIGURE 2. A phosphatome RNAi screen reveals significant regulators of ERK activation.
Following RNAi of individual phosphatases in A549 cells, pERK bands normalised to tubulin loading controls were compared to 10 minute 100 ng/ml EGF positive controls (C+EGF) on each blot and the data ranked (phosphatome mean: solid line, standard deviation: dotted line). The top 10 most significant hits produced approximately 20-25% of the signal generated by acute EGF stimulation and as illustrated in the blot pERK labelling is clearly stronger when they are knocked down compared to a selection of hits representing the phosphatome mean response and the unstimulated A549 control (C-). A c c e p t e d M a n u s c r i p t
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